Page Banner

Notifications & Alerts

Latest Notifications & Alerts

We are pleased to share an update on the replacement of Roche Cobas and Abbott Architect analyzers used nationally at LifeLabs.
All core chemistry and therapeutic drug monitoring (TDM) tests will transition to the Abbott Alinity c platform. This will take place gradually, starting on May 28th 2023 for the tests performed at the Sudbury and Thunder Bay sites, followed by June 11th 2023 for the tests performed at Belleville te...
**Clarification on Specimen Collection** The Aptima collection swabs are suitable ONLY for molecular testing of CT/GC and TV and not suitable for culture. Culture requests for specimens collected in Aptima molecular collection swabs will be rejected. For any culture request such as Genital Cultur...
Starting April 03, 2023, LifeLabs will temporarily refer out all testing for Anti-CCP to an external site to ensure uninterrupted service.
LifeLabs will replace its current platform for molecular testing of Chlamydia/Gonorrhea and Trichomonas in Ontario from the BD Viper System to the Hologic Panther system this spring.

**Removal of race modifier comment**

Aligning with LifeLabs commitment to promoting equity in chronic kidney disease (CKD) test reporting the race modifier comment will be removed from all eGFR results.

Due to unforeseen circumstances, the second phase testing for some of our health care providers in community has not yet been fully transitioned, however, we are planning to complete this gradually throughout the rest of this month.
**Update on Test Availability –Delay in Turnaround Time** Due to a supply chain shortage, this test will temporarily be unavailable. We apologize for the inconvenience.
LifeLabs has partnered with Natera, Inc. to offer SignateraTM, a molecular residual disease test that detects and monitors cancer status by examining an individual’s unique tumour genetic profile.